Vitamin B9

Pharmacology & Research

Vitamin B9 (folate) is a water-soluble B vitamin and the coenzyme backbone of one-carbon metabolism — the pathway that builds DNA and RNA bases, matures red blood cells, and (with vitamin B12) remethylates homocysteine to methionine. Its evidence base is unusually clean at one end and unusually oversold at the other: periconceptional supplementation to prevent neural-tube defects is among the best-proven interventions in preventive medicine, while the “lower your homocysteine, protect your heart” story that drove a decade of supplementation has largely collapsed in large trials. A recurring theme is that folate corrects a deficiency dramatically but adds little on top of adequacy — and that in fortified countries most people are already replete. Form matters at the margins: synthetic folic acid is more bioavailable than food folate but must be reduced by the body, whereas L-methylfolate (5-MTHF) is the already-active circulating form, relevant mainly to people who carry MTHFR variants or take folate-depleting drugs.

1. Neural-tube-defect prevention

The MRC Vitamin Study (1991), a double-blind RCT in 1,817 women with a prior affected pregnancy, found 4 mg/day folic acid before and in early pregnancy cut recurrent neural-tube defects by ~72% ^{1Reference 1MRC Vitamin Study Research Group · 1991RCTPrevention of neural tube defects: results of the Medical Research Council Vitamin Study — [randomised controlled trial]View study →}. The Hungarian trial of Czeizel & Dudás (1992) extended this to first occurrence: a periconceptional multivitamin containing 0.8 mg folic acid essentially eliminated NTDs in ~4,750 women versus trace-element controls ^{2Reference 2Czeizel et al. · 1992RCTPrevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation — [randomised controlled trial]View study →}. These results drove mandatory folic-acid fortification of grain in the US, Canada and dozens of countries, which measurably lowered spina bifida and anencephaly rates. The effect is causal, large, and largely dose-secured at ordinary supplemental amounts; higher (4–5 mg) doses are reserved for prior-NTD pregnancies and some anti-epileptic drug users.

Gap: it must be taken before the neural tube closes (~28 days post-conception), so it only helps women supplementing before they may know they are pregnant — an intake-timing problem, not an efficacy one.

2. Folate-deficiency anaemia

Folate is required for red-cell maturation; a shortfall produces megaloblastic (macrocytic) anaemia indistinguishable on blood film from B12 deficiency. Oral folate reliably corrects the haematology of true folate deficiency, which arises from poor intake, malabsorption (coeliac, alcohol), pregnancy demand, or folate-depleting drugs (methotrexate, some anticonvulsants). This is textbook repletion therapy rather than a “benefit” in replete people.

Gap: correcting the anaemia with folate alone can mask coexisting B12 deficiency while its neurological damage progresses — B12 status must be checked first. This is entirely deficiency-dependent.

3. Homocysteine lowering

Folic acid is the single most effective nutrient for lowering plasma total homocysteine, typically reducing it ~20–25% at 0.5–5 mg/day, with most of the effect achieved by ~0.8 mg; adding B12 and B6 gives a further small drop ^{5,8Reference 5Wang et al. · 2007Meta-analysisEfficacy of folic acid supplementation in stroke prevention: a meta-analysis — [meta-analysis]View study →Reference 8Martí-Carvajal et al. · 2017Systematic reviewHomocysteine-lowering interventions for preventing cardiovascular events — [Cochrane systematic review]View study →}. The biochemistry — 5-MTHF donating a methyl group so B12 can remethylate homocysteine to methionine — is robust and reproducible. The problem is that lower homocysteine has not translated into the vascular protection the “homocysteine hypothesis” predicted (see stroke and the cardiovascular caveat).

Gap: homocysteine is a validated biomarker response, not a validated clinical endpoint here — lowering it does not, in fortified populations, reduce heart attacks.

4. Stroke prevention

The China Stroke Primary Prevention Trial (CSPPT, 2015) randomised 20,702 hypertensive adults without folic-acid fortification to enalapril plus 0.8 mg folic acid versus enalapril alone; first stroke fell from 3.4% to 2.7% over ~4.5 years (HR ~0.79) ^{4Reference 4Huo et al. · 2015RCTEfficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China (CSPPT) — [randomised controlled trial]View study →}. An earlier meta-analysis of folic-acid RCTs found a modest overall stroke reduction concentrated in trials with low baseline folate and no fortification ^{5Reference 5Wang et al. · 2007Meta-analysisEfficacy of folic acid supplementation in stroke prevention: a meta-analysis — [meta-analysis]View study →}. The signal is real but population-specific.

Gap: the benefit appears only where baseline folate is low and grain is unfortified; trials in fortified countries (US/Canada) show no stroke benefit, so this does not generalise to replete populations.

5. Depression (adjunctive L-methylfolate)

Low folate status is associated with poorer antidepressant response, motivating L-methylfolate as an add-on. In a randomised trial, 15 mg/day L-methylfolate added to an SSRI improved response among inadequate responders versus placebo augmentation, with the 15 mg (not 7.5 mg) arm carrying the signal ^{6Reference 6Papakostas et al. · 2014RCTEffect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients — [randomised controlled trial]View study →}. Results across trials are small and inconsistent, and much of the L-methylfolate literature is linked to the product’s manufacturer.

Gap: benefit is modest, concentrated in subgroups (low folate, obesity, inflammation) rather than depression generally, and the strongest data come from industry-associated trials.

6. Cognition in older adults

In the Dutch FACIT trial (2007), 800 mcg/day folic acid for 3 years in 818 older adults with elevated homocysteine and low-normal folate (an unfortified setting) improved memory and information-processing speed relative to placebo ^{7Reference 7Durga et al. · 2007RCTEffect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial — [randomised controlled trial]View study →}. This is one well-conducted RCT in a specific population; trials in folate-replete elders have generally not shown cognitive benefit, and folic acid has not been shown to prevent dementia.

Gap: a single positive RCT restricted to older adults with raised homocysteine and no fortification — it does not support routine folate for cognition in replete people.

Mechanisms

Target / pathway	Effect	Relevant to
Tetrahydrofolate (THF) one-carbon pool	Donates single-carbon units for purine and thymidylate synthesis	DNA/RNA synthesis, cell division, NTD prevention, anaemia
5-methyl-THF → methionine synthase (B12-dependent)	Remethylates homocysteine to methionine; regenerates SAM methyl donor	Homocysteine lowering, methylation reactions
Thymidylate synthase / dUMP→dTMP	Supplies methyl for thymidine; deficiency causes uracil misincorporation	Megaloblastic anaemia, rapidly dividing tissue
MTHFR enzyme (C677T variant)	Converts 5,10-methylene-THF to 5-methyl-THF; variant lowers activity	Rationale for L-methylfolate in variant carriers

Pharmacokinetics

Synthetic folic acid taken on an empty stomach is ~85–100% bioavailable; natural food folate is roughly 50% as available, which is why intakes are expressed in dietary folate equivalents (DFE): 1 mcg DFE = 1 mcg food folate = 0.6 mcg folic acid from fortified food/supplements with meals = 0.5 mcg folic acid on an empty stomach ^{11Reference 11EFSA NDA Panel · 2022Conversion of calcium-L-methylfolate and (6S)-5-methyltetrahydrofolic acid glucosamine salt into dietary folate equivalents — [regulatory opinion]View study →}. Absorbed folic acid is reduced in the intestine and liver to THF and 5-methyl-THF, the main circulating form; the liver stores roughly 10–30 mg, about half the body’s total, giving a buffer of months before deficiency appears. Excess is renally excreted. At high supplemental doses (typically above ~200–400 mcg per dose) the intestinal reduction capacity is exceeded and unmetabolised folic acid appears in blood — the basis for the B12-masking concern and for interest in L-methylfolate, which bypasses reduction. Plasma half-life of a folate dose is short (hours), but tissue turnover is slow.

Clinical trials

Folate is off-patent and cheaply fortified, so most large trials are publicly funded (fortification epidemiology, CSPPT, homocysteine/cardiovascular RCTs); the main commercially sponsored activity is around branded L-methylfolate (5-MTHF) products.

Last checked: July 2026.

Dietary Sources

Folate is concentrated in dark leafy greens, legumes, liver and certain vegetables and fruit; the name derives from the Latin folium (“leaf”). Since mandatory fortification, enriched grain products (bread, pasta, cereal, rice) are also a major source in many countries and supply the more-bioavailable synthetic folic acid. Natural food folate is roughly half as bioavailable as folic acid, and is easily destroyed by prolonged cooking, boiling (it leaches into water) and food processing — which is why refined, unfortified grains are poor sources.

Food	Serving	Folate (approx.)
Beef liver	85 g	~215 mcg DFE
Lentils / chickpeas (cooked)	½ cup	~180 mcg DFE
Spinach (cooked)	½ cup	~130 mcg DFE
Asparagus	½ cup	~130 mcg DFE
Fortified breakfast cereal	1 serving	~100–400 mcg DFE
Avocado	½ fruit	~60 mcg DFE
Broccoli (cooked)	½ cup	~50 mcg DFE
Orange	1 medium	~30 mcg DFE

Values approximate; from the NIH ODS Folate fact sheet ^{10Reference 10National Institutes of Health · 2024ReviewFolate — Fact Sheet for Health Professionals — [authoritative review]. https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/View study →}. Intakes are expressed in dietary folate equivalents (DFE) because folic acid is ~1.7× more bioavailable than food folate.

Dosage & Intake

Reference intakes (adults): the RDA is 400 mcg DFE/day, rising to 600 mcg DFE/day in pregnancy and 500 mcg DFE in lactation ^{10Reference 10National Institutes of Health · 2024ReviewFolate — Fact Sheet for Health Professionals — [authoritative review]. https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/View study →}. Because of the neural-tube-defect window, women who could become pregnant are advised to get 400 mcg/day of folic acid from fortified food or a supplement in addition to food folate — the supplemental amount, not just total intake, is what the trial evidence supports ^{1,2Reference 1MRC Vitamin Study Research Group · 1991RCTPrevention of neural tube defects: results of the Medical Research Council Vitamin Study — [randomised controlled trial]View study →Reference 2Czeizel et al. · 1992RCTPrevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation — [randomised controlled trial]View study →}. Women with a prior NTD-affected pregnancy are usually prescribed 4,000 mcg (4 mg)/day under medical supervision.

Supplemental ranges studied: 400–800 mcg/day (general/prenatal), 0.8 mg (stroke and homocysteine trials ^{4,5Reference 4Huo et al. · 2015RCTEfficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China (CSPPT) — [randomised controlled trial]View study →Reference 5Wang et al. · 2007Meta-analysisEfficacy of folic acid supplementation in stroke prevention: a meta-analysis — [meta-analysis]View study →}), up to 5 mg (high-risk pregnancy, homocysteine research), and 7.5–15 mg L-methylfolate (depression augmentation ^{6Reference 6Papakostas et al. · 2014RCTEffect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients — [randomised controlled trial]View study →}).

DFE conversion (important): 1 mcg DFE = 1 mcg food folate = 0.6 mcg folic acid taken with food = 0.5 mcg folic acid on an empty stomach. A “400 mcg folic acid” supplement label therefore equals ~667 mcg DFE. Form: folic acid and L-methylfolate (5-MTHF) are both effective at raising folate status; 5-MTHF is the already-active form and is marketed to MTHFR-variant carriers, but for most people the practical difference is small and the choice is mainly about avoiding unmetabolised folic acid at high doses.

These are doses studied in research, not a personal recommendation.

Safety

Folate has a wide safety margin; food folate has no upper limit and no reported toxicity. The UL of 1,000 mcg/day applies only to synthetic folic acid from supplements and fortified food. The dose-limiting concern is not folate toxicity but masking: high folic-acid intake can correct the megaloblastic anaemia of vitamin B12 deficiency while the neurological damage of that deficiency continues undetected — so B12 status should be assessed before high-dose folate, especially in older adults and vegans. High circulating unmetabolised folic acid at large doses is a topic of ongoing research (possible immune and, from the colorectal-adenoma data, growth-promotion signals ^{9Reference 9Cole et al. · 2007RCTFolic acid for the prevention of colorectal adenomas: a randomized clinical trial — [RCT]View study →}) but is not established as harmful at ordinary intakes; overall cancer incidence was not raised in a large meta-analysis ^{3Reference 3Vollset et al. · 2013Meta-analysisEffects of folic acid supplementation on overall and site-specific cancer incidence during randomised trials — [meta-analysis]View study →}.

Interactions: folate antagonists and depleters include methotrexate (folinic-acid, not folic-acid, rescue is used deliberately in oncology; folate supplementation is standard in low-dose methotrexate for rheumatoid arthritis), anticonvulsants (phenytoin, carbamazepine, valproate — mutual depletion; folate may modestly lower phenytoin levels), sulfasalazine and trimethoprim (dihydrofolate reductase inhibition), and chronic alcohol use. Space folate and these drugs and monitor as clinically indicated.

Pregnancy & lactation

Verdict: recommended and protective. Adequate folate before conception and in the first trimester is one of the best-evidenced prenatal interventions, sharply reducing neural-tube defects ^{1,2Reference 1MRC Vitamin Study Research Group · 1991RCTPrevention of neural tube defects: results of the Medical Research Council Vitamin Study — [randomised controlled trial]View study →Reference 2Czeizel et al. · 1992RCTPrevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation — [randomised controlled trial]View study →}; 400–800 mcg/day supplemental folic acid is standard, with higher medically supervised doses for prior-NTD or anticonvulsant-exposed pregnancies. There is no evidence of harm from recommended prenatal doses.

Scope of this safety review (for honesty, not a claim):

• Interactions assessed? Yes — methotrexate, anticonvulsants (phenytoin/carbamazepine/valproate), sulfasalazine, trimethoprim, and alcohol are the principal folate-depleting or antagonising agents.
• Pregnancy/lactation assessed? Yes — folate is actively recommended periconceptionally and in pregnancy; protective, not merely tolerated.
• Upper Limit? Yes — 1,000 mcg/day for synthetic folic acid (supplements/fortified food); no UL for food folate. This is a masking limit, not a toxicity limit.

References